Aripiprazole (OPC-14597) monohydrate, an atypical antipsychotic, is a potent and high-affinity dopamine D2 receptor partial agonist. Aripiprazole monohydrate is an inverse agonist at 5-HT2B and 5-HT2A receptors and displays partial agonist actions at 5-HT1A, 5-HT2C, D3, and D4 receptors. Aripiprazole monohydrate can be used for the research of schizophrenia and COVID19^[1][2][3][4].

Aripiprazole monohydrate potently activates D2 receptor-mediated inhibition of cAMP accumulation^[1].
Aripiprazole monohydrate shows a greater anti-inflammatory effect on TNF-α, IL-13, IL-17α and fractalkine^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Aripiprazole monohydrate (0-3 mg/kg, IP, daily) shows some anxiolytic properties^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

466.40

C₂₃H₂₉Cl₂N₃O₃

851220-85-4

Room temperature in continental US; may vary elsewhere.

• [1]. Burris KD, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):381-9.  [Content Brief]

  [2]. Davies MA, et al. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev. 2004 Winter;10(4):317-36.  [Content Brief]

  [3]. Crespo-Facorro B, et al. Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis. Front Pharmacol. 2021 Mar 2;12:646701.  [Content Brief]

  [4]. Russo E, et al. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology. 2013 Jan;64:371-9.  [Content Brief]